Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12969346 | 0.93 | ADORA2A (0.86) | ADORA2AADORA1 | |
| Preladenant SCHEMBL2856554 | 0.93 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL21832807 | 0.91 | ADORA2A (0.87) | ADORA2AADORA1 | |
| SCHEMBL30858798 | 0.90 | ADORA2A (0.88) | ADORA2AADORA1 | |
| SCHEMBL21833625 | 0.90 | ADORA2A (0.86) | ADORA2AADORA1 | |
| SCHEMBL30543453 | 0.90 | ADORA2A (0.88) | ADORA2AADORA1 | |
| SCHEMBL8287839 | 0.90 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL21833111 | 0.90 | ADORA2A (0.84) | ADORA2AADORA1 | |
| SCHEMBL14922357 | 0.89 | ADORA2A (0.83) | ADORA2AADORA1 | |
| SCHEMBL8243358 | 0.89 | ADORA2A (0.85) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326241-A1 | PROCESS FOR PREPARING SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINES | SCHERING CORPORATION | 2009-12-31 | — | — | US | disclosed |
| US-20090326241-A1 | PROCESS FOR PREPARING SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINES | SCHERING CORPORATION | 2009-12-31 | — | — | US | disclosed |
| US-7601833-B2 | Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines | SCHERING CORPORATION (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601833-B2 | Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines | SCHERING CORPORATION (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090005559-A1 | PROCESS FOR PREPARING SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINES | MERCK SHARP & DOHME LLC | 2009-01-01 | — | — | US | disclosed |
| US-20090005559-A1 | PROCESS FOR PREPARING SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINES | MERCK SHARP & DOHME LLC | 2009-01-01 | — | — | US | disclosed |
| US-7439361-B2 | Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines | SCHERING CORPORATION (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439361-B2 | Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines | SCHERING CORPORATION (US) | 2008-10-21 | — | — | US | disclosed |
| US-20070203340-A1 | Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines | MERCK SHARP & DOHME LLC | 2007-08-30 | — | — | US | disclosed |
| US-20070203340-A1 | Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines | MERCK SHARP & DOHME LLC | 2007-08-30 | — | — | US | disclosed |
| US-7223861-B2 | Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidines | SCHERING CORPORATION (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223861-B2 | Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidines | SCHERING CORPORATION (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050090492-A1 | Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine | SCHERING CORPORATION | 2005-04-28 | — | — | US | disclosed |
| US-20050090492-A1 | Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine | SCHERING CORPORATION | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326241-A1 | PROCESS FOR PREPARING SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINES | TYMP, DCK, TK1 | ADORA2A 665/4885ADORA1 196/4885 |
| US-20070203340-A1 | Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines | TYMP, DCK, TK1 | ADORA2A 665/4885ADORA1 196/4885 |
| US-20050090492-A1 | Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine | TYMP, DCK, TK1 | ADORA2A 553/4885ADORA1 175/4885 |
| US-20090005559-A1 | PROCESS FOR PREPARING SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINES | TYMP, DCK, TK1 | ADORA2A 665/4885ADORA1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.